ArticleBMC gastroenterology2025
Hepatitis B and C infections, and co-infections screening among patients attending a tertiary hospital in Addis Ababa, Ethiopia: a retrospective database study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B and C virus infection is a continuous public health problem in Ethiopia, with the prevalence of the disease significantly varying across administrative regions. Determining seroprevalence among people who are unaware of their infection status is essential for hepatitis diagnosis and treatment. We aimed to determine the seroprevalence of two hepatitis viruses among patients attending different service areas in a tertiary hospital in Ethiopia.
methodsWe conducted an institution-based retrospective study using serology laboratory data from January 2021 to December 2023 at Yekatit 12 Hospital Medical College in Addis Ababa. We retrieved hepatitis B virus and hepatitis C virus data from electronic databases. We ran a binary logistic regression analysis to assess the relationship between dependent and independent variables. Statistical significance was determined for variables having a P-value (P < 0.05) and 95% confidence intervals.
resultsA total of 3332 and 9890 patients’ blood samples were screened for hepatitis B and C virus, respectively. The prevalence of hepatitis B was 5.4% (179/3332), and hepatitis C virus was 1.8% (175/9890). The overall prevalence of co-infection was 0.2% (7/3322). Hepatitis B virus prevalence fluctuated, while hepatitis C virus prevalence steadily increased from 2021 to 2023. The positivity rate of the hepatitis B virus is 5.4% (89/1643) and hepatitis C virus 1.86% (93/5414) among female patients. Age was significantly associated with hepatitis B and C virus infection. The two viruses have been found at a significantly higher prevalence rate among admitted and emergency department patients.
conclusionAn intermediate seroprevalence of HBV and hepatitis C virus infection was detected among participants in our study area. Screening for hepatitis B and C can be beneficial in identifying people with viral hepatitis and offering a chance to engage them in specialized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.